Clarus Therapeutics Holdings, Inc. (CRXT) Stock Overview
Explore Clarus Therapeutics Holdings, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Clarus Therapeutics Holdings, Inc. (CRXT)
Key Financials
Key Financials
Market Cap
0
P/E Ratio
-0.02
EPS (TTM)
$-2.80
ROE
-4.63%
CRXT Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Clarus Therapeutics Holdings, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of CRXT on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $N/A for the NASDAQ listing.
Key metrics behind Clarus Therapeutics Holdings, Inc.'s NASDAQ-traded stock include a P/E ratio of -0.02 and a market capitalization of 0. Combined with our AI analysis, these give both institutional and retail investors a clear view of CRXT on the NASDAQ.